1. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma
by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun Lakshman, Angela Dispenzieri, Dragan Jevremovic, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Eli Muchtar, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson I. Gonsalves, Rahma Warsame, Taxiarchis V. Kourelis, Yi Lisa Hwa, Prashant Kapoor, Nelson Leung, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, and Shaji K. Kumar
BloodAdv
Volume 2(22):
November 27, 2018
© 2018 by The American Society of Hematology

2. Mohammed A. Aljama et al. Blood Adv 2018;2:3149-3154
© 2018 by The American Society of Hematology

3. Risk for progression to myeloma or related disorder in 306 patients with SMM, using a PCPI cutoff of 0.5.
Risk for progression to myeloma or related disorder in 306 patients with SMM, using a PCPI cutoff of 0.5.
Mohammed A. Aljama et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Distribution of events in SMM patients at time of progression.
Mohammed A. Aljama et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology